• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.

    2/14/25 8:18:09 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Affimed N.V.

    (Name of Issuer)


    Common Shares, nominal value 0.01 per share

    (Title of Class of Securities)


    N01045207

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    N01045207


    1Names of Reporting Persons

    683 Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    654,600.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    654,600.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    654,600.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    N01045207


    1Names of Reporting Persons

    683 Capital Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    654,600.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    654,600.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    654,600.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    N01045207


    1Names of Reporting Persons

    Ari Zweiman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    654,600.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    654,600.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    654,600.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Affimed N.V.
    (b)Address of issuer's principal executive offices:

    GOTTLIEB-DAIMLER-STRASSE 2 MANNHEIM, GERMANY 68165
    Item 2. 
    (a)Name of person filing:

    683 Capital Management, LLC 683 Capital Partners, LP Ari Zweiman
    (b)Address or principal business office or, if none, residence:

    The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
    (c)Citizenship:

    683 Capital Management, LLC - DELAWARE 683 Capital Partners, LP - DELAWARE Ari Zweiman - UNITED STATES
    (d)Title of class of securities:

    Common Shares, nominal value 0.01 per share
    (e)CUSIP No.:

    N01045207
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of December 31, 2024, 683 Capital Partners, LP beneficially owned 654,600 Common Shares. 683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the 654,600 Common Shares beneficially owned by 683 Capital Partners, LP. Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the 654,600 Common Shares beneficially owned by 683 Capital Management, LLC. The following percentage is based on 15,227,463 Common Shares outstanding as of June 30, 2024, as disclosed in the Issuer's Form F-3 filed on November 4, 2024. As of December 31, 2024, the Reporting Persons may be deemed to have beneficially owned approximately 4.3% of the outstanding Common Shares.
    (b)Percent of class:

    4.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit A to Schedule 13G filed on October 24, 2024.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    683 Capital Management, LLC
     
    Signature:Ari Zweiman
    Name/Title:Managing Member
    Date:02/14/2025
     
    683 Capital Partners, LP
     
    Signature:Ari Zweiman
    Name/Title:Authorized Person
    Date:02/14/2025
     
    Ari Zweiman
     
    Signature:Ari Zweiman
    Name/Title:Self
    Date:02/14/2025
    Get the next $AFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFMD

    DatePrice TargetRatingAnalyst
    12/12/2022$6.00Buy
    H.C. Wainwright
    10/10/2022$9.00 → $2.00Buy → Hold
    Stifel
    8/18/2022Overweight
    Wells Fargo
    3/31/2022$7.00Overweight
    Piper Sandler
    2/23/2022$12.00Overweight
    Cantor Fitzgerald
    10/21/2021$10.00Buy
    Truist
    10/12/2021$13.00 → $12.00Outperform
    SVB Leerink
    9/30/2021$12.00Buy
    Stifel
    More analyst ratings

    $AFMD
    SEC Filings

    See more
    • SEC Form NT 20-F filed by Affimed N.V.

      NT 20-F - Affimed N.V. (0001608390) (Filer)

      5/1/25 4:05:20 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Affimed N.V.

      6-K - Affimed N.V. (0001608390) (Filer)

      4/21/25 8:32:58 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.

      SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)

      2/14/25 8:18:09 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

      An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex

      4/29/25 10:00:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

      MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations. Det

      4/23/25 10:05:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

      MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3

      4/21/25 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AFMD
    Financials

    Live finance-specific insights

    See more
    • SEC Form SC 13G filed by Affimed N.V.

      SC 13G - Affimed N.V. (0001608390) (Subject)

      10/24/24 2:49:52 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/14/24 4:07:21 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/13/24 1:20:05 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

      MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in

      12/9/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Reports Third Quarter 2024 Financial Results & Business Update

      AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected

      11/14/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

      MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r

      11/6/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Affimed Appoints Shawn M. Leland as Chief Executive Officer

      MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO). Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. He has a proven track record in successfully advancing the development of novel oncology assets, rais

      9/3/24 7:45:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

      HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. "We are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board," said Dr. Thomas Hecht, Chairman of Affimed's Supervisory Board. "Constanze brings a wealth of legal expertise and a deep understanding of the biotech and he

      6/22/23 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

      HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. "We are pleased to welcome Uta to Affimed's Supervisory Board," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "Uta brings unique and very deep and extensive executive experience in the life sciences industry. With over 20 years of leadership roles in driving higher busine

      6/16/21 7:04:39 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Affimed Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00

      12/12/22 7:32:36 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Affimed Therapeutics from Buy to Hold and set a new price target of $2.00 from $9.00 previously

      10/10/22 7:08:28 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Affimed Therapeutics

      Wells Fargo resumed coverage of Affimed Therapeutics with a rating of Overweight

      8/18/22 10:27:27 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care